Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
Related reading
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
GSK blood cancer drug reapproved by EU regulator
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda